Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Diabetic nephropathy has severe individual and societal consequences, owing to its high morbidity, mortality and health-care costs Despite the availability of anti-glycaemic, renoprotective and ...

It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...